Long-term ALS survival benefit with CNM-Au8 seen in trial analyses

TDP-43 as a therapeutic target in neurodegenerative diseases: Focusing on motor neuron disease and frontotemporal dementia - ScienceDirect

Clene Reports Significant Long-Term Survival Improvement From CNM-Au8 Treatment in HEALEY ALS Platform Trial Compared to PRO-ACT Historical Controls -September 25, 2023 at 07:01 am EDT

Trial Results from Clene Nanomedicine Strike ALS Research

Form 8-K Clene Inc. For: Mar 14

Latest Research News

Innovating Clinical Trials for Amyotrophic Lateral Sclerosis

Amyotrophic lateral sclerosis: a neurodegenerative disorder poised for successful therapeutic translation. - Abstract - Europe PMC

Efficacy and safety of CNM-Au8 in amyotrophic lateral sclerosis (RESCUE-ALS study): a phase 2, randomised, double-blind, placebo-controlled trial and open label extension - eClinicalMedicine

Articles about Clene Nanomedicine, Inc